Extension Study for Patients Entered Into Study Infacort 003
Status:
Completed
Trial end date:
2018-08-10
Target enrollment:
Participant gender:
Summary
A Phase 3, open-label, single-group, non-randomised, observational study of the safety and
biochemical disease control of Infacort® in neonates, infants and children with adrenal
insufficiency and congenital adrenal hyperplasia who had completed study Infacort 003. All
subjects who had satisfactorily completed study Infacort 003 were offered the opportunity to
take part in Infacort 004.